{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:04Z","timestamp":1792782544992,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to prospectively compare clinician-reported acute toxicity and patient-reported health-related quality of life (HRQoL) between daily cone-beam CT (CBCT)-based online adaptive radiotherapy (oART) and image-guided radiotherapy (IGRT) in patients with localized prostate cancer treated with moderate hypofractionation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      In this prospective study, 74\u00a0patients with localized prostate cancer received either CBCT-based oART (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u200943) or CBCT-based IGRT (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u200931) with\u00a062\/57.6\/48\u202fGy in 20\u00a0fractions, allocated pragmatically by convenience. Acute gastrointestinal (GI) and genitourinary (GU) toxicity was assessed weekly using CTCAE v5.0, and HRQoL was evaluated using the EORTC QLQ-C30 questionnaire at baseline and the end of therapy. Between-group differences were tested using Boschloo\u2019s exact test, Wilcoxon rank-sum test and\n                      <jats:italic>t<\/jats:italic>\n                      -tests; temporal and between-group changes were evaluated based on minimally clinically important differences (MCIDs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline patient and treatment characteristics were similar, except for more high-\/very high-risk tumors in the oART group (40.5% vs.\u00a09.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.03). Online ART was associated with more favorable gastrointestinal toxicity, reflected by lower maximum toxicity grades (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.028). Maximum genitourinary toxicity was comparable between groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.793). More IGRT patients exceeded MCID thresholds for fatigue (74% vs.\u00a037%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.004), physical functioning (27% vs.\u00a03%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.009), and role functioning (48.1% vs. 22.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.04). Differences for global health, pain, social function, and diarrhea were not statistically significant but consistently favored oART.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Daily CBCT-based oART and IGRT were both well tolerated, with low rates of high-grade acute toxicity. In this exploratory analysis, oART was associated with a\u00a0more favorable GI toxicity profile and better preservation of HRQoL. These hypothesis-generating findings suggest that adaptive workflows may provide measurable patient-centered benefits during prostate radiotherapy and warrant confirmation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02596-z","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:15:11Z","timestamp":1790331311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute toxicity and patient-reported quality of life during daily online adaptive radiotherapy versus conventional IGRT for localized prostate cancer: a\u00a0prospective parallel cohort study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-1546","authenticated-orcid":false,"given":"Goda","family":"Kalinauskaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise A.","family":"K\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Rubarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Dannehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"H\u00f6hne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Senger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2596_CR1","doi-asserted-by":"publisher","unstructured":"de Crevoisier\u00a0R, Bayar\u00a0MA, Pommier\u00a0P, Muracciole\u00a0X, P\u00eane\u00a0F, Dudouet\u00a0P, Latorzeff\u00a0I, Beckendorf\u00a0V, Bachaud\u00a0JM, Laplanche\u00a0A et\u00a0al (2018) Daily versus weekly prostate cancer image guided radiation therapy: phase\u00a03 multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2018;102:1420\u20131429.  \u00a0https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2006","DOI":"10.1016\/j.ijrobp.2018.07.2006"},{"key":"2596_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","volume":"26","author":"J Nikitas","year":"2025","unstructured":"Nikitas\u00a0J, Jamshidian\u00a0P, Tree\u00a0AC, Hall\u00a0E, Dearnaley\u00a0D, Michalski\u00a0JM, Lee\u00a0WR, Nguyen\u00a0PL, Sandler\u00a0HM, Catton\u00a0CN et\u00a0al (2025) The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol 26:378\u2013386. https:\/\/doi.org\/10.1016\/S1470-2045(24)00720-4","journal-title":"Lancet Oncol"},{"key":"2596_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061206","volume":"16","author":"OM Dona Lemus","year":"2024","unstructured":"Dona Lemus\u00a0OM, Cao\u00a0M, Cai\u00a0B, Cummings\u00a0M, Zheng\u00a0D (2024) Adaptive radiotherapy: next-generation radiotherapy. Cancers 16:1206. https:\/\/doi.org\/10.3390\/cancers16061206\u00a0","journal-title":"Cancers"},{"key":"2596_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2025.101874","volume":"10","author":"G Kalinauskaite","year":"2025","unstructured":"Kalinauskaite\u00a0G, K\u00fcnzel\u00a0LA, Kluge\u00a0A, Rubarth\u00a0K, Dannehl\u00a0J, H\u00f6hne\u00a0C, Beck\u00a0M, Zips\u00a0D, Senger\u00a0C (2025) Optimizing workflow for cone beam computed tomography-based online adaptive radiation therapy toward reduced physician involvement. Adv Radiat Oncol 10:101874. https:\/\/doi.org\/10.1016\/j.adro.2025.101874","journal-title":"Adv Radiat Oncol"},{"key":"2596_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1308406","volume":"14","author":"CA Fink","year":"2024","unstructured":"Fink\u00a0CA, Buchele\u00a0C, Baumann\u00a0L, Liermann\u00a0J, Hoegen\u00a0P, Ristau\u00a0J, Regnery\u00a0S, Sandrini\u00a0E, K\u00f6nig\u00a0L, Rippke\u00a0C et\u00a0al (2024) Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer. Front Oncol 14:1308406. https:\/\/doi.org\/10.3389\/fonc.2024.1308406\u00a0","journal-title":"Front Oncol"},{"key":"2596_CR6","doi-asserted-by":"publisher","unstructured":"Hall\u00a0WA, Raaijmakers\u00a0F, Tree\u00a0A, Christodouleas\u00a0JP, Van Der Voort vanZyp\u00a0J, Van Der Heide\u00a0U, Pos\u00a0FJ, Westhoff\u00a0P, Choudhury\u00a0A, Vesprini\u00a0D et\u00a0al (2025) Daily online adaptive recontouring for prostate cancer using 1.5 tesla magnetic resonance image guidance (MRgRT) improves patient reported urinary symptoms, a prospective, international, observational cohort study (NCT04075305).\u00a0Int J Radiat Oncol Biol Phys. 2025;123:S81\u2013S82. \u00a0https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.1104","DOI":"10.1016\/j.ijrobp.2025.06.1104"},{"key":"2596_CR7","doi-asserted-by":"publisher","unstructured":"Zhu\u00a0LL, Bredfeldt\u00a0JS, Hu\u00a0YH, Hancox\u00a0C, Guthier\u00a0CV, Quirk\u00a0S, Pursley\u00a0J, Kamran\u00a0SC, McClatchy\u00a0D, Nguyen\u00a0PL et\u00a0al (2025) CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatment.\u00a0Clin Transl Radiat Oncol.. 2025;213:111207. \u00a0https:\/\/doi.org\/10.1016\/j.radonc.2025.111207","DOI":"10.1016\/j.radonc.2025.111207"},{"key":"2596_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctro.2021.09.003","volume":"31","author":"RO Kowalchuk","year":"2021","unstructured":"Kowalchuk\u00a0RO, Hillman\u00a0D, Daniels\u00a0TB, Vargas\u00a0CE, Rwigema\u00a0JCM, Wong\u00a0WW, Stish\u00a0BJ, Dueck\u00a0AC, Choo\u00a0R (2021) Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. Clin Transl Radiat Oncol 31:34\u201341. https:\/\/doi.org\/10.1016\/j.ctro.2021.09.003","journal-title":"Clin Transl Radiat Oncol"},{"key":"2596_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071670","volume":"14","author":"AC Nuijens","year":"2022","unstructured":"Nuijens\u00a0AC, Oei\u00a0AL, Bouhuijs\u00a0A, Franken\u00a0NAP, Rasch\u00a0CRN, Stalpers\u00a0LJA (2022) A comparison between patient- and physician-reported late radiation toxicity in long-term prostate cancer survivors. Cancers 14:1670. https:\/\/doi.org\/10.3390\/cancers14071670","journal-title":"Cancers"},{"key":"2596_CR10","doi-asserted-by":"publisher","unstructured":"Ong\u00a0WL, Nikitas\u00a0J, Joseph\u00a0D, Steigler\u00a0A, Millar\u00a0J, Valle\u00a0L, Steinberg\u00a0ML, Ma\u00a0TM, Reiter\u00a0RE, Rettig\u00a0MB et\u00a0al (2024) Long-term quality-of-life outcomes after prostate radiation therapy with or without high-dose-rate brachytherapy boost: post hoc analysis of TROG 03.04 RADAR.\u00a0Int J Radiat Onco Biol Phys. 2024;119:813\u2013825.\u00a0https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.051","DOI":"10.1016\/j.ijrobp.2023.09.051"},{"key":"2596_CR11","doi-asserted-by":"publisher","unstructured":"Lievens\u00a0Y, Borras\u00a0JM, Grau\u00a0C, Aggarwal\u00a0A (2021) Value-based radiotherapy: a\u00a0new chapter of the ESTRO-HERO project.\u00a0 Clin Transl Radiat Oncol.. 2021;160:236\u2013239.\u00a0https:\/\/doi.org\/10.1016\/j.radonc.2021.05.007","DOI":"10.1016\/j.radonc.2021.05.007"},{"key":"2596_CR12","unstructured":"Schaeffer EM, Srinivas N, Ahmed B, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, D\u2019Amico AV (2025) NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer."},{"key":"2596_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2025.101092","volume":"57","author":"G Kalinauskaite","year":"2026","unstructured":"Kalinauskaite\u00a0G, K\u00fcnzel\u00a0LA, Rubarth\u00a0K, Nguyen\u00a0T, Dannehl\u00a0J, H\u00f6hne\u00a0C, Beck\u00a0M, Bauer\u00a0J, Zips\u00a0D, Senger\u00a0C (2026) Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer. Clin Transl Radiat Oncol 57:101092. https:\/\/doi.org\/10.1016\/j.ctro.2025.101092","journal-title":"Clin Transl Radiat Oncol"},{"key":"2596_CR14","unstructured":"EORTC (2001) EORTC QLQ-C30 Scoring Manual. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf. Accessed 27 Feb 2025 (Internet)"},{"key":"2596_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","volume":"188","author":"JZ Musoro","year":"2023","unstructured":"Musoro\u00a0JZ, Coens\u00a0C, Sprangers\u00a0MAG, Brandberg\u00a0Y, Groenvold\u00a0M, Flechtner\u00a0HH, Cocks\u00a0K, Velikova\u00a0G, Dirven\u00a0L, Greimel\u00a0E et\u00a0al (2023) Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer 188:171\u2013182. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.027","journal-title":"Eur J Cancer"},{"key":"2596_CR16","doi-asserted-by":"publisher","unstructured":"Lock\u00a0M, Best\u00a0L, Wong\u00a0E, Bauman\u00a0G, D\u2019Souza\u00a0D, Venkatesan\u00a0V, Sexton\u00a0T, Ahmad\u00a0B, Izawa\u00a0J, Rodrigues\u00a0G (2011) A\u00a0phase\u00a0II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.\u00a0Int J Radiat Oncol Biol Phys. 2011;80:1306\u20131315. \u00a0https:\/\/doi.org\/10.1016\/j.ijrobp.2010.04.054","DOI":"10.1016\/j.ijrobp.2010.04.054"},{"key":"2596_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","volume":"26","author":"AC Tree","year":"2025","unstructured":"Tree\u00a0AC, Hinder\u00a0V, Chan\u00a0A, Tolan\u00a0S, Ostler\u00a0P, Van Der Voet\u00a0H, Kancherla\u00a0K, Loblaw\u00a0A, Naismith\u00a0O, Jain\u00a0S et\u00a0al (2025) Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 26:936\u2013947. https:\/\/doi.org\/10.1016\/S1470-2045(25)00205-0","journal-title":"Lancet Oncol"},{"key":"2596_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100742","volume":"46","author":"K Sritharan","year":"2024","unstructured":"Sritharan\u00a0K, Daamen\u00a0L, Pathmanathan\u00a0A, Schytte\u00a0T, Pos\u00a0F, Choudhury\u00a0A, van der Voort van Zyp\u00a0JRN, Kerkmeijer\u00a0LGW, Hall\u00a0W, Hall\u00a0E et\u00a0al (2024) MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study. Clin Transl Radiat Oncol 46:100742. https:\/\/doi.org\/10.1016\/j.ctro.2024.100742\u00a0","journal-title":"Clin Transl Radiat Oncol"},{"key":"2596_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00066-018-1395-y","volume":"195","author":"E Rammant","year":"2019","unstructured":"Rammant\u00a0E, Ost\u00a0P, Swimberghe\u00a0M, Vanderstraeten\u00a0B, Lumen\u00a0N, Decaestecker\u00a0K, Bultijnck\u00a0R, De Meerleer\u00a0G, Sarrazyn\u00a0C, Colman\u00a0R et\u00a0al (2019) Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial. Strahlenther Onkol 195:393\u2013401. https:\/\/doi.org\/10.1007\/s00066-018-1395-y","journal-title":"Strahlenther Onkol"},{"key":"2596_CR20","doi-asserted-by":"publisher","first-page":"454.e1","DOI":"10.1016\/j.urolonc.2023.08.001","volume":"41","author":"C Tillier","year":"2023","unstructured":"Tillier\u00a0C, Boekhout\u00a0A, Veerman\u00a0H, Wollersheim\u00a0B, Groen\u00a0P, Van Der Poel\u00a0H, Van De Poll-Franse\u00a0L (2023) Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: impact on management. Urol Oncol 41:454.e1\u2013454.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.001","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"2596_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson\u00a0P, Nilsson\u00a0P, Gunnlaugsson\u00a0A, Beckman\u00a0L, Tavelin\u00a0B, Norman\u00a0D, Thellenberg-Karlsson\u00a0C, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J et\u00a0al (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22:235\u2013245. https:\/\/doi.org\/10.1016\/S1470-2045(20)30581-7","journal-title":"Lancet Oncol"},{"key":"2596_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","volume":"13","author":"D Dearnaley","year":"2012","unstructured":"Dearnaley\u00a0D, Syndikus\u00a0I, Sumo\u00a0G, Bidmead\u00a0M, Bloomfield\u00a0D, Clark\u00a0C, Gao\u00a0A, Hassan\u00a0S, Horwich\u00a0A, Huddart\u00a0R et\u00a0al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13:43\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(11)70293-5","journal-title":"Lancet Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02596-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:02:43Z","timestamp":1790377363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02596-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":22,"alternative-id":["2596"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02596-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Zips: discloses financial technical and educational support for scientific projects received by the Department of Radiation Oncology T\u00fcbingen and Charit\u00e9 (Elekta, Philips, Varian\/Siemens, Sennewald, Therapanacea, and PTW). Presentation fees for the mentioned industrial partners were paid to the University of T\u00fcbingen and Charit\u00e9. G.\u00a0Kalinauskaite, L.A.\u00a0K\u00fcnzel, K.\u00a0Rubarth, J.\u00a0Dannehl, C.\u00a0H\u00f6hne, M.\u00a0Beck, A.\u00a0Gr\u00fcn, J.\u00a0Bauer, T.\u00a0Wiegel, R.\u00a0Thamm, and C.\u00a0Senger disclose financial technical and educational support from Varian Medical Systems provided to the Department of Radiation Oncology, Charit\u00e9.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}